Personalized Medicine – News and Features

Researchers developed a 3-in-1 antibody that targets tumors, delivers treatment, and activates immune cells to enhance T-cell response. The customizable, scalable method shows potential for safer and quicker precision cancer therapy.

Researchers have used microcellular "drones" to deliver antisense oligonucleotide therapeutics to lung cancer cells.

A new study from Charité University reveals that the biomarker Ki67 can predict if inflammatory bowel disease patients will respond to vedolizumab. Machine learning identified Ki67 levels as a marker for treatment resistance.

Using CRISPR-Cas13, NYU researchers reveal that noncoding RNAs, previously deemed “junk,” are crucial for cell function and development. Their findings, published in Cell, identify nearly 800 essential noncoding RNAs.

A team created UAB36, a polygenic score based on 36 genes linked to drug resistance, showing promise in predicting cancer treatment outcomes.UAB36 outperformed other scores, offering a potential tool for tailoring personalized cancer therapies.

Researchers discovered that gene deserts, non-coding DNA regions, regulate heart and embryo development through enhancer elements controlling key genes. This insight into gene deserts’ role in heart health could aid genetic diagnostics.

A study reveals that triple-negative breast cancer cells prompt immune cells to form "molecular bridges," leading to immune suppression. An antibody treatment blocking these bridges shows promise in enhancing the immune response.

A study from the Buck Institute reveals that threonine, an essential amino acid, could extend lifespan in both fruit flies and humans. By utilizing machine learning and systems biology, researchers linked key metabolites between species.

Researchers trained and validated an AI model based on MRI scans from more than 700 prostate cancer patients. The model was able to identify and demarcate the edges of 85% of the most radiologically aggressive prostate lesions.

At this year’s HUPO annual meeting, the 24th version of the Human Protein Atlas has launched. We interviewed the HPA's program director, Professor Mathias Uhlén, to learn about its new features.